Corrigendum to: Pulmonary Hypertension in Heart Failure Patients

Login or register to view PDF.
Creative Commons Licence
 
Received date
23 October 2020
Accepted date
23 October 2020
DOI
https://doi.org/10.15420/cfr.2020.1.1
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

In the article by Rao et al. entitled Pulmonary Hypertension in Heart Failure Patients (Cardiac Failure Review 2020;6:e05. https://doi.org/10.15420/cfr.2019.09), the following correction should be made.

The authors incorrectly stated that higher TAPSE/PASP correlates with “higher levels of natriuretic peptides, worse systemic and pulmonary haemodynamics and abnormal exercise aerobic capacity”, when it should have stated that lower TAPSE/PASP correlates with those outcomes.

The corrected sentence reads:

“Guazzi et al. showed it could be used to prognosticate in HFpEF patients, with lower TAPSE/PASP correlating with higher levels of natriuretic peptides, worse systemic and pulmonary haemodynamics and abnormal exercise aerobic capacity.”

The authors and Cardiac Failure Review apologise for this error.